 Judith Regensteiner
Concepts (505)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intermittent Claudication | 44 | 2022 | 108 | 5.360 |
Why?
| | Diabetes Mellitus, Type 2 | 54 | 2024 | 2098 | 5.150 |
Why?
| | Exercise | 46 | 2022 | 1644 | 3.790 |
Why?
| | Peripheral Arterial Disease | 24 | 2022 | 380 | 3.750 |
Why?
| | Exercise Therapy | 31 | 2022 | 351 | 3.310 |
Why?
| | Sex Characteristics | 16 | 2023 | 635 | 2.960 |
Why?
| | Peripheral Vascular Diseases | 24 | 2011 | 98 | 2.530 |
Why?
| | Oxygen Consumption | 33 | 2021 | 588 | 2.330 |
Why?
| | Walking | 23 | 2022 | 424 | 2.190 |
Why?
| | Cardiovascular Diseases | 22 | 2024 | 1729 | 2.160 |
Why?
| | Sex Factors | 13 | 2022 | 1721 | 1.940 |
Why?
| | Exercise Test | 37 | 2019 | 545 | 1.540 |
Why?
| | Diabetes Mellitus | 16 | 2022 | 906 | 1.530 |
Why?
| | Biomedical Research | 7 | 2023 | 585 | 1.470 |
Why?
| | Cardiology | 6 | 2023 | 259 | 1.300 |
Why?
| | Quality of Life | 18 | 2019 | 2359 | 1.270 |
Why?
| | Exercise Tolerance | 14 | 2024 | 213 | 1.260 |
Why?
| | American Heart Association | 10 | 2019 | 264 | 1.230 |
Why?
| | Leg | 13 | 2021 | 227 | 1.120 |
Why?
| | Research Personnel | 4 | 2020 | 151 | 1.060 |
Why?
| | Mentoring | 3 | 2022 | 101 | 1.000 |
Why?
| | Women's Health | 8 | 2023 | 271 | 0.970 |
Why?
| | Humans | 172 | 2024 | 115039 | 0.960 |
Why?
| | Vascular Stiffness | 3 | 2023 | 408 | 0.910 |
Why?
| | Diabetic Angiopathies | 6 | 2017 | 244 | 0.890 |
Why?
| | Muscle, Skeletal | 13 | 2021 | 1477 | 0.860 |
Why?
| | Community Health Services | 2 | 2015 | 211 | 0.820 |
Why?
| | Cardiovascular System | 5 | 2023 | 126 | 0.820 |
Why?
| | Education, Medical | 3 | 2020 | 221 | 0.810 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2016 | 34 | 0.800 |
Why?
| | Female | 95 | 2023 | 59611 | 0.780 |
Why?
| | Insulin Resistance | 12 | 2024 | 1077 | 0.760 |
Why?
| | Lower Extremity | 9 | 2019 | 337 | 0.750 |
Why?
| | Male | 90 | 2023 | 55730 | 0.740 |
Why?
| | Obesity | 19 | 2023 | 2524 | 0.710 |
Why?
| | Arterial Occlusive Diseases | 7 | 2015 | 73 | 0.710 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 25 | 0.700 |
Why?
| | Cardiorespiratory Fitness | 2 | 2019 | 35 | 0.680 |
Why?
| | Aged | 54 | 2022 | 19119 | 0.680 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 850 | 0.670 |
Why?
| | Hypoglycemic Agents | 9 | 2021 | 1006 | 0.660 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 30 | 0.660 |
Why?
| | Middle Aged | 68 | 2019 | 26827 | 0.660 |
Why?
| | Surveys and Questionnaires | 21 | 2018 | 4631 | 0.660 |
Why?
| | Diastole | 1 | 2019 | 131 | 0.640 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 43 | 0.640 |
Why?
| | Gender Identity | 1 | 2019 | 101 | 0.620 |
Why?
| | Physical Fitness | 9 | 2016 | 179 | 0.610 |
Why?
| | Metabolomics | 2 | 2020 | 527 | 0.610 |
Why?
| | Hypertension | 6 | 2022 | 1058 | 0.610 |
Why?
| | Blood Pressure | 12 | 2021 | 1539 | 0.580 |
Why?
| | Brachial Artery | 6 | 2015 | 178 | 0.580 |
Why?
| | Health Status | 4 | 2020 | 722 | 0.580 |
Why?
| | United States | 35 | 2023 | 12224 | 0.580 |
Why?
| | Curriculum | 2 | 2020 | 843 | 0.570 |
Why?
| | Physical Exertion | 7 | 2009 | 211 | 0.560 |
Why?
| | Venoms | 1 | 2016 | 30 | 0.550 |
Why?
| | Vasodilator Agents | 3 | 2010 | 307 | 0.500 |
Why?
| | Sleep | 1 | 2020 | 631 | 0.490 |
Why?
| | Life Style | 9 | 2018 | 431 | 0.480 |
Why?
| | Cardiac Rehabilitation | 3 | 2019 | 33 | 0.480 |
Why?
| | National Institutes of Health (U.S.) | 4 | 2023 | 106 | 0.470 |
Why?
| | Research Design | 4 | 2019 | 930 | 0.460 |
Why?
| | Home Care Services | 4 | 2019 | 222 | 0.430 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2016 | 361 | 0.430 |
Why?
| | Physicians | 4 | 2022 | 772 | 0.430 |
Why?
| | Risk Factors | 27 | 2022 | 8642 | 0.420 |
Why?
| | Microcirculation | 4 | 2017 | 135 | 0.420 |
Why?
| | Mentors | 4 | 2022 | 158 | 0.410 |
Why?
| | Advisory Committees | 5 | 2019 | 208 | 0.410 |
Why?
| | Arteriosclerosis | 4 | 2002 | 82 | 0.410 |
Why?
| | Blood Flow Velocity | 4 | 2009 | 390 | 0.390 |
Why?
| | Peptides | 1 | 2016 | 849 | 0.380 |
Why?
| | Weight Loss | 6 | 2016 | 641 | 0.380 |
Why?
| | Treatment Outcome | 23 | 2022 | 9122 | 0.370 |
Why?
| | Diabetes Mellitus, Type 1 | 8 | 2021 | 3245 | 0.370 |
Why?
| | Mitochondria, Muscle | 3 | 2018 | 93 | 0.360 |
Why?
| | Disability Evaluation | 2 | 2011 | 271 | 0.360 |
Why?
| | Ankle | 3 | 2008 | 70 | 0.360 |
Why?
| | Longevity | 2 | 2022 | 137 | 0.350 |
Why?
| | Gait | 2 | 2006 | 249 | 0.350 |
Why?
| | Faculty, Medical | 4 | 2022 | 232 | 0.350 |
Why?
| | Regional Blood Flow | 11 | 2020 | 428 | 0.330 |
Why?
| | Tetrazoles | 3 | 2006 | 32 | 0.330 |
Why?
| | Physical Endurance | 3 | 2011 | 231 | 0.320 |
Why?
| | Cardiac Output, Low | 1 | 2009 | 64 | 0.320 |
Why?
| | Adult | 35 | 2021 | 30655 | 0.320 |
Why?
| | Oxygen | 4 | 2018 | 855 | 0.320 |
Why?
| | Fear | 1 | 2011 | 292 | 0.310 |
Why?
| | Recovery of Function | 9 | 2019 | 575 | 0.310 |
Why?
| | Thiazolidinediones | 3 | 2010 | 143 | 0.310 |
Why?
| | Cost of Illness | 3 | 2018 | 254 | 0.310 |
Why?
| | Double-Blind Method | 6 | 2019 | 1664 | 0.310 |
Why?
| | Research Support as Topic | 2 | 2020 | 108 | 0.310 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 156 | 0.300 |
Why?
| | Blood Glucose | 10 | 2024 | 1821 | 0.300 |
Why?
| | Activities of Daily Living | 5 | 2021 | 351 | 0.290 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2020 | 100 | 0.290 |
Why?
| | Perception | 1 | 2009 | 310 | 0.280 |
Why?
| | Hematologic Agents | 1 | 2006 | 2 | 0.280 |
Why?
| | Medicare | 2 | 2022 | 666 | 0.280 |
Why?
| | Stents | 6 | 2015 | 476 | 0.280 |
Why?
| | Feasibility Studies | 2 | 2022 | 746 | 0.260 |
Why?
| | Disease Management | 4 | 2017 | 563 | 0.260 |
Why?
| | Motor Activity | 5 | 2012 | 642 | 0.260 |
Why?
| | Foundations | 2 | 2018 | 22 | 0.250 |
Why?
| | Vascular Surgical Procedures | 5 | 2009 | 259 | 0.250 |
Why?
| | Vascular Diseases | 4 | 2000 | 231 | 0.250 |
Why?
| | Societies, Medical | 3 | 2017 | 678 | 0.250 |
Why?
| | Insulin | 5 | 2020 | 2082 | 0.250 |
Why?
| | Echocardiography | 4 | 2018 | 557 | 0.250 |
Why?
| | Interdisciplinary Studies | 2 | 2017 | 27 | 0.240 |
Why?
| | Vasodilation | 3 | 2015 | 417 | 0.240 |
Why?
| | Heart Rate | 6 | 2015 | 705 | 0.240 |
Why?
| | Overweight | 6 | 2023 | 474 | 0.240 |
Why?
| | Respiration | 3 | 1990 | 182 | 0.230 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 208 | 0.220 |
Why?
| | Kinetics | 5 | 2015 | 1558 | 0.220 |
Why?
| | Fibrinolysis | 2 | 2003 | 160 | 0.220 |
Why?
| | Medroxyprogesterone | 4 | 1991 | 10 | 0.220 |
Why?
| | Minority Groups | 2 | 2022 | 228 | 0.220 |
Why?
| | Lung Diseases | 3 | 2019 | 703 | 0.220 |
Why?
| | Iliac Artery | 2 | 2014 | 44 | 0.220 |
Why?
| | Muscles | 7 | 1994 | 324 | 0.210 |
Why?
| | Polyhydroxyethyl Methacrylate | 1 | 2002 | 10 | 0.210 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 1812 | 0.210 |
Why?
| | Financing, Organized | 2 | 2020 | 33 | 0.210 |
Why?
| | Financial Management | 1 | 2022 | 15 | 0.210 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1398 | 0.210 |
Why?
| | Vitamin E | 1 | 2003 | 110 | 0.210 |
Why?
| | Endovascular Procedures | 2 | 2018 | 268 | 0.210 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 82 | 0.210 |
Why?
| | Glucose Intolerance | 1 | 2024 | 137 | 0.200 |
Why?
| | Ascorbic Acid | 1 | 2003 | 110 | 0.200 |
Why?
| | Academic Medical Centers | 3 | 2020 | 412 | 0.200 |
Why?
| | Estrogens, Conjugated (USP) | 3 | 1991 | 34 | 0.190 |
Why?
| | Arginine | 1 | 2003 | 238 | 0.190 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2551 | 0.190 |
Why?
| | Adiponectin | 2 | 2016 | 212 | 0.190 |
Why?
| | Congresses as Topic | 2 | 2020 | 198 | 0.190 |
Why?
| | Placebos | 3 | 2019 | 198 | 0.190 |
Why?
| | Organizational Innovation | 2 | 2020 | 133 | 0.190 |
Why?
| | Echocardiography, Doppler | 3 | 2016 | 92 | 0.190 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 185 | 0.190 |
Why?
| | Sulfonylurea Compounds | 2 | 2019 | 44 | 0.180 |
Why?
| | Sex Distribution | 2 | 2020 | 335 | 0.180 |
Why?
| | Cardiovascular Agents | 2 | 2014 | 125 | 0.180 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 173 | 0.180 |
Why?
| | Patient Compliance | 4 | 2015 | 524 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2006 | 1214 | 0.170 |
Why?
| | Hemodynamics | 6 | 2009 | 1017 | 0.170 |
Why?
| | Time Factors | 10 | 2018 | 6141 | 0.170 |
Why?
| | Body Mass Index | 9 | 2017 | 1967 | 0.170 |
Why?
| | Pediatric Obesity | 2 | 2017 | 492 | 0.170 |
Why?
| | Adolescent | 12 | 2022 | 17862 | 0.170 |
Why?
| | Arteries | 3 | 2016 | 249 | 0.170 |
Why?
| | Forearm | 2 | 2015 | 114 | 0.170 |
Why?
| | Cross-Sectional Studies | 8 | 2014 | 4411 | 0.170 |
Why?
| | Body Composition | 5 | 2014 | 586 | 0.170 |
Why?
| | Leadership | 2 | 2020 | 295 | 0.160 |
Why?
| | Follow-Up Studies | 7 | 2016 | 4420 | 0.160 |
Why?
| | Telerehabilitation | 1 | 2019 | 29 | 0.160 |
Why?
| | Cause of Death | 1 | 2020 | 364 | 0.160 |
Why?
| | Resistance Training | 1 | 2020 | 113 | 0.150 |
Why?
| | Aged, 80 and over | 8 | 2012 | 6357 | 0.150 |
Why?
| | Women's Rights | 1 | 2017 | 3 | 0.150 |
Why?
| | Pentoxifylline | 3 | 2006 | 21 | 0.150 |
Why?
| | Sexism | 1 | 2018 | 43 | 0.150 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 160 | 0.150 |
Why?
| | Program Development | 1 | 2019 | 346 | 0.150 |
Why?
| | Health Status Indicators | 4 | 2015 | 154 | 0.140 |
Why?
| | Colorado | 9 | 2017 | 4089 | 0.140 |
Why?
| | Caregivers | 2 | 2022 | 712 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 2020 | 354 | 0.140 |
Why?
| | Heart Diseases | 2 | 2019 | 330 | 0.140 |
Why?
| | Capillaries | 3 | 2012 | 91 | 0.140 |
Why?
| | Precision Medicine | 1 | 2020 | 340 | 0.140 |
Why?
| | Ankle Brachial Index | 2 | 2014 | 30 | 0.140 |
Why?
| | Case-Control Studies | 6 | 2016 | 3015 | 0.140 |
Why?
| | Microvessels | 1 | 2017 | 68 | 0.140 |
Why?
| | Clinical Trials as Topic | 5 | 2019 | 937 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2018 | 201 | 0.130 |
Why?
| | Needs Assessment | 1 | 2018 | 316 | 0.130 |
Why?
| | Glucose Tolerance Test | 4 | 2024 | 344 | 0.130 |
Why?
| | Reference Values | 4 | 2007 | 748 | 0.130 |
Why?
| | Faculty | 1 | 2017 | 130 | 0.130 |
Why?
| | Ischemia | 1 | 2019 | 363 | 0.130 |
Why?
| | Leptin | 1 | 2017 | 211 | 0.130 |
Why?
| | Blood Vessels | 1 | 2017 | 180 | 0.130 |
Why?
| | Adiposity | 2 | 2017 | 466 | 0.130 |
Why?
| | Pilot Projects | 2 | 2015 | 1375 | 0.120 |
Why?
| | Plethysmography | 3 | 2011 | 104 | 0.120 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 68 | 0.120 |
Why?
| | Program Evaluation | 2 | 2020 | 825 | 0.120 |
Why?
| | Myocardium | 1 | 2020 | 922 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2021 | 1085 | 0.120 |
Why?
| | Cardiac Output | 1 | 2015 | 143 | 0.120 |
Why?
| | Ventricular Function | 1 | 2015 | 56 | 0.120 |
Why?
| | Hypoxia | 3 | 1990 | 958 | 0.120 |
Why?
| | Physical Education and Training | 1 | 1994 | 61 | 0.120 |
Why?
| | Arterial Pressure | 1 | 2015 | 99 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 372 | 0.120 |
Why?
| | Endothelium | 1 | 2015 | 112 | 0.120 |
Why?
| | Patient Selection | 4 | 2019 | 646 | 0.120 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1995 | 120 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 197 | 0.110 |
Why?
| | Hyperlipidemias | 3 | 2004 | 122 | 0.110 |
Why?
| | Health Care Costs | 2 | 2014 | 381 | 0.110 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 22 | 0.110 |
Why?
| | Menopause | 3 | 1991 | 271 | 0.110 |
Why?
| | Angioplasty | 2 | 2009 | 40 | 0.110 |
Why?
| | Reaction Time | 1 | 2015 | 375 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2014 | 108 | 0.110 |
Why?
| | Diet, Reducing | 1 | 2013 | 79 | 0.110 |
Why?
| | Diabetes Complications | 3 | 2010 | 212 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 469 | 0.110 |
Why?
| | Diabetic Nephropathies | 2 | 2014 | 234 | 0.100 |
Why?
| | Students, Medical | 1 | 2017 | 272 | 0.100 |
Why?
| | Interviews as Topic | 3 | 2020 | 584 | 0.100 |
Why?
| | Kidney | 2 | 2021 | 1186 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2014 | 482 | 0.100 |
Why?
| | Smoking | 6 | 2010 | 1392 | 0.100 |
Why?
| | Capacity Building | 1 | 2012 | 51 | 0.100 |
Why?
| | Counseling | 1 | 2015 | 342 | 0.100 |
Why?
| | Premenopause | 2 | 2003 | 107 | 0.100 |
Why?
| | Clinical Protocols | 1 | 1993 | 234 | 0.100 |
Why?
| | Heart Ventricles | 1 | 2016 | 714 | 0.100 |
Why?
| | Myocardial Revascularization | 1 | 2011 | 67 | 0.100 |
Why?
| | Health Promotion | 1 | 2017 | 686 | 0.100 |
Why?
| | Linear Models | 2 | 2014 | 776 | 0.100 |
Why?
| | Benchmarking | 1 | 2012 | 161 | 0.090 |
Why?
| | Research Report | 1 | 2011 | 75 | 0.090 |
Why?
| | Comorbidity | 4 | 2021 | 1457 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 214 | 0.090 |
Why?
| | Consensus | 3 | 2019 | 534 | 0.090 |
Why?
| | Biomarkers | 5 | 2017 | 3419 | 0.090 |
Why?
| | Hemoglobins | 2 | 2017 | 315 | 0.090 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 50 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2009 | 151 | 0.090 |
Why?
| | Hyperemia | 1 | 2011 | 45 | 0.090 |
Why?
| | Affect | 1 | 2012 | 246 | 0.090 |
Why?
| | Atherosclerosis | 2 | 2011 | 342 | 0.090 |
Why?
| | Coronary Disease | 4 | 2004 | 347 | 0.090 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2009 | 103 | 0.090 |
Why?
| | Niacin | 1 | 2010 | 18 | 0.090 |
Why?
| | Lovastatin | 1 | 2010 | 26 | 0.090 |
Why?
| | C-Reactive Protein | 2 | 2009 | 363 | 0.090 |
Why?
| | Hospitalization | 1 | 2018 | 1754 | 0.090 |
Why?
| | Body Fat Distribution | 1 | 2009 | 44 | 0.080 |
Why?
| | Gonadal Steroid Hormones | 1 | 1990 | 124 | 0.080 |
Why?
| | Heart Failure | 3 | 2018 | 1962 | 0.080 |
Why?
| | Psychometrics | 1 | 2012 | 608 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 499 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2009 | 59 | 0.080 |
Why?
| | Hyperinsulinism | 2 | 2010 | 103 | 0.080 |
Why?
| | Age Factors | 4 | 2021 | 2894 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 63 | 0.080 |
Why?
| | Aorta | 1 | 2011 | 389 | 0.080 |
Why?
| | Fasting | 2 | 2005 | 242 | 0.080 |
Why?
| | Thinness | 1 | 2009 | 87 | 0.080 |
Why?
| | Perfusion | 1 | 2009 | 151 | 0.080 |
Why?
| | Mitochondria | 1 | 2014 | 750 | 0.080 |
Why?
| | Analysis of Variance | 4 | 2012 | 1229 | 0.080 |
Why?
| | Puberty | 1 | 2009 | 137 | 0.080 |
Why?
| | Inflammation | 3 | 2009 | 2485 | 0.080 |
Why?
| | Aging | 1 | 2018 | 1624 | 0.070 |
Why?
| | Young Adult | 5 | 2017 | 10498 | 0.070 |
Why?
| | Cost-Benefit Analysis | 4 | 2014 | 544 | 0.070 |
Why?
| | Angina Pectoris | 1 | 2008 | 63 | 0.070 |
Why?
| | Myoglobin | 1 | 2007 | 14 | 0.070 |
Why?
| | Prospective Studies | 8 | 2019 | 6232 | 0.070 |
Why?
| | Leisure Activities | 2 | 2006 | 25 | 0.070 |
Why?
| | Prevalence | 3 | 2019 | 2255 | 0.070 |
Why?
| | Awareness | 1 | 2008 | 92 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1184 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2106 | 0.070 |
Why?
| | Dyspnea | 1 | 2008 | 218 | 0.070 |
Why?
| | Regression Analysis | 5 | 1998 | 948 | 0.070 |
Why?
| | Glycation End Products, Advanced | 1 | 2006 | 57 | 0.070 |
Why?
| | Chronic Disease | 2 | 2023 | 1591 | 0.070 |
Why?
| | Animals | 5 | 2018 | 31867 | 0.060 |
Why?
| | Metformin | 2 | 2010 | 278 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 586 | 0.060 |
Why?
| | Blood Viscosity | 2 | 1995 | 16 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2009 | 676 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2004 | 250 | 0.060 |
Why?
| | Pulmonary Circulation | 1 | 2007 | 407 | 0.060 |
Why?
| | Hematocrit | 2 | 1995 | 85 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 181 | 0.060 |
Why?
| | Sulfonic Acids | 1 | 2004 | 12 | 0.060 |
Why?
| | Nutrition Surveys | 1 | 2006 | 224 | 0.060 |
Why?
| | Cohort Studies | 3 | 2016 | 4904 | 0.060 |
Why?
| | Incidence | 3 | 2019 | 2318 | 0.060 |
Why?
| | Carnitine | 4 | 1996 | 62 | 0.060 |
Why?
| | Population Dynamics | 1 | 1985 | 128 | 0.060 |
Why?
| | Estrogens | 2 | 2010 | 313 | 0.060 |
Why?
| | Acetates | 1 | 2004 | 95 | 0.060 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 94 | 0.060 |
Why?
| | Body Weight | 2 | 2006 | 873 | 0.060 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 136 | 0.060 |
Why?
| | Biopsy | 3 | 2012 | 1046 | 0.060 |
Why?
| | Child | 5 | 2017 | 18407 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2004 | 291 | 0.050 |
Why?
| | Intracranial Arterial Diseases | 1 | 2002 | 6 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 3334 | 0.050 |
Why?
| | Musculoskeletal Diseases | 1 | 2003 | 54 | 0.050 |
Why?
| | Dietary Fats | 1 | 2004 | 290 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2004 | 258 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3595 | 0.050 |
Why?
| | Alcohol Drinking | 2 | 2010 | 655 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 281 | 0.050 |
Why?
| | Serum Globulins | 1 | 2002 | 4 | 0.050 |
Why?
| | Ambulatory Care | 2 | 2014 | 478 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2004 | 280 | 0.050 |
Why?
| | Diet | 2 | 2010 | 1076 | 0.050 |
Why?
| | Qualitative Research | 2 | 2020 | 935 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2005 | 558 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2013 | 258 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2002 | 83 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 752 | 0.050 |
Why?
| | Homocysteine | 1 | 2002 | 136 | 0.050 |
Why?
| | Altitude | 1 | 1985 | 434 | 0.050 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2002 | 399 | 0.050 |
Why?
| | Fibrinogen | 1 | 2002 | 155 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2002 | 161 | 0.050 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 257 | 0.050 |
Why?
| | Multivariate Analysis | 3 | 2014 | 1435 | 0.050 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2000 | 30 | 0.050 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 307 | 0.050 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 180 | 0.050 |
Why?
| | Administration, Oral | 1 | 2003 | 730 | 0.040 |
Why?
| | Pregnancy | 3 | 2020 | 5519 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 236 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 696 | 0.040 |
Why?
| | Medroxyprogesterone Acetate | 2 | 1990 | 28 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2002 | 227 | 0.040 |
Why?
| | Specialties, Surgical | 1 | 2000 | 70 | 0.040 |
Why?
| | Rural Population | 2 | 1995 | 446 | 0.040 |
Why?
| | Organization and Administration | 1 | 2019 | 8 | 0.040 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 71 | 0.040 |
Why?
| | Sports Medicine | 2 | 2010 | 97 | 0.040 |
Why?
| | Femoral Artery | 2 | 2011 | 168 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 87 | 0.040 |
Why?
| | Asia | 1 | 2018 | 53 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 75 | 0.040 |
Why?
| | Depression | 1 | 2007 | 1136 | 0.040 |
Why?
| | Public Health | 1 | 2023 | 435 | 0.040 |
Why?
| | Densitometry | 1 | 1998 | 29 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2366 | 0.040 |
Why?
| | Lactic Acid | 2 | 1998 | 278 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 122 | 0.040 |
Why?
| | Hypercapnia | 2 | 1989 | 51 | 0.040 |
Why?
| | Walking Speed | 1 | 2018 | 35 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 230 | 0.040 |
Why?
| | Cell Respiration | 1 | 2018 | 74 | 0.040 |
Why?
| | Autonomic Nervous System | 1 | 1998 | 70 | 0.040 |
Why?
| | Walk Test | 1 | 2018 | 52 | 0.040 |
Why?
| | Hand Strength | 1 | 2018 | 95 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 222 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2013 | 2799 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 955 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 48 | 0.040 |
Why?
| | Career Choice | 1 | 2019 | 181 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 915 | 0.040 |
Why?
| | Neural Conduction | 2 | 1995 | 79 | 0.040 |
Why?
| | Caloric Restriction | 1 | 2018 | 90 | 0.040 |
Why?
| | Capillary Resistance | 1 | 2017 | 5 | 0.040 |
Why?
| | Family Practice | 1 | 2001 | 427 | 0.040 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 94 | 0.040 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 20 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.040 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 47 | 0.040 |
Why?
| | Canada | 1 | 2018 | 322 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1715 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 528 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 84 | 0.030 |
Why?
| | Forecasting | 2 | 2000 | 332 | 0.030 |
Why?
| | Heart | 1 | 2020 | 610 | 0.030 |
Why?
| | Stroke Volume | 1 | 2018 | 510 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 337 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2007 | 12547 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 33 | 0.030 |
Why?
| | Energy Intake | 3 | 2006 | 421 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2016 | 223 | 0.030 |
Why?
| | Risk | 1 | 2017 | 815 | 0.030 |
Why?
| | Databases, Factual | 2 | 2011 | 1132 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 62 | 0.030 |
Why?
| | Electrophysiology | 1 | 1995 | 201 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 682 | 0.030 |
Why?
| | Vascular Patency | 1 | 2014 | 97 | 0.030 |
Why?
| | Life Expectancy | 1 | 2014 | 51 | 0.030 |
Why?
| | Models, Economic | 1 | 2014 | 48 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 101 | 0.030 |
Why?
| | Phosphorus | 1 | 2014 | 81 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 447 | 0.030 |
Why?
| | Hospital Costs | 1 | 2014 | 103 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 210 | 0.030 |
Why?
| | Drug Costs | 1 | 2014 | 91 | 0.030 |
Why?
| | Health Behavior | 1 | 2019 | 704 | 0.030 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 127 | 0.030 |
Why?
| | Health Education | 1 | 2016 | 323 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 184 | 0.030 |
Why?
| | Carotid Stenosis | 1 | 2014 | 79 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 675 | 0.030 |
Why?
| | Collateral Circulation | 2 | 2003 | 19 | 0.030 |
Why?
| | Creatinine | 1 | 2014 | 425 | 0.030 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 113 | 0.030 |
Why?
| | Administrative Personnel | 1 | 2012 | 29 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 676 | 0.030 |
Why?
| | Waist Circumference | 1 | 2012 | 123 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2013 | 298 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1321 | 0.030 |
Why?
| | Treatment Failure | 1 | 2013 | 332 | 0.030 |
Why?
| | North Carolina | 1 | 2012 | 97 | 0.020 |
Why?
| | Health Planning | 1 | 1992 | 46 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 271 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 66 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2014 | 227 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2014 | 399 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1992 | 83 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2014 | 604 | 0.020 |
Why?
| | Popliteal Artery | 1 | 2011 | 59 | 0.020 |
Why?
| | Estrone | 1 | 1991 | 35 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1991 | 163 | 0.020 |
Why?
| | C-Peptide | 1 | 1991 | 138 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 814 | 0.020 |
Why?
| | Follicular Phase | 1 | 1990 | 36 | 0.020 |
Why?
| | Metabolism | 1 | 1990 | 35 | 0.020 |
Why?
| | Luteal Phase | 1 | 1990 | 41 | 0.020 |
Why?
| | Incretins | 1 | 2010 | 15 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 481 | 0.020 |
Why?
| | Actigraphy | 1 | 2010 | 74 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 58 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2010 | 93 | 0.020 |
Why?
| | Acetylcarnitine | 1 | 1989 | 4 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 976 | 0.020 |
Why?
| | Progesterone | 1 | 1991 | 232 | 0.020 |
Why?
| | Health Services Research | 1 | 2012 | 371 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 797 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 445 | 0.020 |
Why?
| | Risk Assessment | 2 | 2009 | 2976 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2010 | 159 | 0.020 |
Why?
| | Energy Metabolism | 3 | 2006 | 729 | 0.020 |
Why?
| | Respiration Disorders | 1 | 1989 | 68 | 0.020 |
Why?
| | Estradiol | 1 | 1991 | 455 | 0.020 |
Why?
| | Partial Pressure | 1 | 1988 | 30 | 0.020 |
Why?
| | Tidal Volume | 1 | 1988 | 76 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 347 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2389 | 0.020 |
Why?
| | Pain | 1 | 1993 | 709 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 201 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 41 | 0.020 |
Why?
| | Testosterone | 1 | 2010 | 343 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2010 | 293 | 0.020 |
Why?
| | Caspase 3 | 1 | 2007 | 237 | 0.020 |
Why?
| | Ankle Joint | 1 | 2008 | 154 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2007 | 179 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 29 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 1988 | 218 | 0.020 |
Why?
| | Income | 1 | 2007 | 167 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 1989 | 232 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2007 | 791 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2006 | 201 | 0.020 |
Why?
| | Sterol O-Acyltransferase | 1 | 2004 | 4 | 0.020 |
Why?
| | Acetamides | 1 | 2004 | 25 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 62 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 340 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3116 | 0.010 |
Why?
| | Gene Transfer Techniques | 1 | 2004 | 147 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2004 | 168 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2004 | 205 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 475 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 1843 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 349 | 0.010 |
Why?
| | Sulfonamides | 1 | 2004 | 445 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1488 | 0.010 |
Why?
| | Artificial Limbs | 1 | 2003 | 116 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2001 | 105 | 0.010 |
Why?
| | Wound Healing | 1 | 2003 | 259 | 0.010 |
Why?
| | Lactates | 2 | 1992 | 84 | 0.010 |
Why?
| | World Health Organization | 1 | 2000 | 103 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 196 | 0.010 |
Why?
| | Logistic Models | 1 | 2004 | 1839 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1636 | 0.010 |
Why?
| | Indians, North American | 1 | 2004 | 570 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 2002 | 339 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 1998 | 79 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2000 | 517 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2000 | 580 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1998 | 149 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 1996 | 185 | 0.010 |
Why?
| | Rehabilitation | 1 | 1992 | 13 | 0.010 |
Why?
| | Electromyography | 1 | 1992 | 326 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1991 | 184 | 0.010 |
Why?
| | Hydroxybutyrates | 1 | 1989 | 10 | 0.010 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 1989 | 14 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 1989 | 74 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1992 | 252 | 0.010 |
Why?
| | Action Potentials | 1 | 1992 | 406 | 0.010 |
Why?
| | Ultrasonics | 1 | 1989 | 46 | 0.010 |
Why?
| | Sleep Apnea Syndromes | 1 | 1989 | 74 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 287 | 0.000 |
Why?
| | Mice | 1 | 1989 | 14927 | 0.000 |
Why?
|
|
Regensteiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|